WYE-687 is a novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin (mTOR). The mammalian target of rapamycin (mTOR) is centrally involved in cell growth, metabolism, and angiogenesis. WYE-687 as one of the pyrazolopyrimidine ATP-competitive mTOR inhibitors, with significant selectivity over phosphatidylinositol 3-kinase (PI3K) isofoms (>100-fold). Unlike the rapalogs, these inhibitors acutely blocked substrate phosphorylation by mTORC1 and mTORC2 in vitro and in cells in response to growth factor, amino acids, and hyperactive PI3K/AKT. Unlike the inhibitors of PI3K or dual-pan PI3K/mTOR, cellular inhibition of P-S6K1 (T389) and P-AKT (S473) by the pyrazolopyrimidines occurred at significantly lower inhibitor concentrations than those of P-AKT (T308) (PI3K-PDK1 readout), showing mTOR selectivity in cellular setting.
|Source||PLoS One (2017). Figure 1. WYE-687|
|Method||MTT viability assay|
|Cell Lines||human RCC cells|
|Incubation Time||72 h|
|Results||MTT viability assay results demonstrated that WYE-687 dose-dependently reduced786-O cell survival, and the MTT OD of 786-O cells was significantly decreasedafter10-1000 nM of WYE-687 treatment|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.
Wahdan-Alaswad RS et al. Mol Cancer Res. 2012 Jun;10(6):821-33. PMID: 22452883.
|Related mTOR Products|
CZ415 is a potent ATP-competitive mTOR inhibitor with very good cell permeability.
GNE-477 is a potent and efficacious dual PI3K (IC50=4 nM)/mTOR(Ki=21 nM) inhibitor.
Zotarolimus (ABT-578) is an analogue of rapamycin, and inhibits FKBP-12 binding with IC50 of 2.8 nM.
LY303511 is a structural analogue of LY294002, which does not inhibit PI3K, increased homotypic GJIC.
Temsirolimus (CCI-779) is a specific mTOR inhibitor with IC50 of 1.76 μM.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.